Kangmei Pharmaceutical: Wholly-owned subsidiary to make up for taxes and late fees, expected to impact net profit in 2025.

Kangmei Pharmaceutical announced that its wholly-owned subsidiary Tengwangge Pharmaceutical recently received a "Tax Processing Decision Letter", requiring the payment of corporate income tax of 4.136 million yuan and late fees for the years 2020-2024. The company must make the payment and adjust its accounts within 15 days, with no tax administrative penalties involved. This matter is expected to affect the company's net profit attributable to shareholders of the listed company by approximately 5.184 million yuan in 2025, without affecting the retrospective adjustment of previous financial data or the company's normal production and operations.